Range Biotechnologies

Range Biotechnologies (Range Bio) is a proteomics company developing an end-to-end platform for what it calls translational proteomics: measurement tools designed to move protein biomarkers from discovery into validated, scalable clinical and industrial use. The company distinguishes discovery proteomics, which screens thousands of candidate proteins in small paired cohorts to identify biomarkers, from translation, which requires validation in larger and more diverse cohorts and deployment as a test that can run at scale. Its technology is described as enabling accurate quantification of multiple proteins across many samples simultaneously, supporting insight into disease mechanisms and how they change over time.

The company positions proteins as dynamic indicators of health that complement genomic information, and frames its longer-term aim as longitudinal, self-to-self health monitoring rather than comparison of an individual measurement against a population reference range. Stated application areas include diagnostic medicine, pharmacodynamics, drug discovery, liquid biopsy and food safety. Its expertise is listed as targeted protein quantification, biomarker discovery and validation, proteomics data analysis, and assay scale-up and process optimization, offered alongside research and development services for diagnostic and drug-development use cases.

Founding story

The company was founded by former labmates Dr. Brandon Wilson and Dr. Nicolo Maganzini together with Professor Tom Soh of Stanford University; Wilson met his co-founders while pursuing a PhD in chemical engineering at Stanford, and the group had worked together for more than eight years on technologies for quantifying human physiology. Wilson has said the founders started the company because their technologies would otherwise have remained within academia. The founding concept drew on an analogy attributed to the late Professor Sam Gambhir and reinforced by Wilson's PhD advisor Tom Soh: that cars, planes and devices are continuously monitored by sensors while comparatively little is known about the human body at any given time. The founders also viewed current diagnostics as limited because molecular measurements are compared with population statistics despite high biological variability, leading to the goal of longitudinal self-to-self tracking. Wilson describes the founding team's expertise as spanning molecular biology, chemistry, computer science, material science and electrical engineering.

Business model

Range Bio offers translational proteomics services and research and development work centered on targeted protein quantification and the translation of protein biomarkers into diagnostic and drug-development applications, and it describes building a technology platform intended to enable new measurement modalities across multiple markets.

Sources describe translational proteomics services and research and development services for diagnostics and drug development, but do not detail pricing or revenue mechanics.

Traction

The company closed a $5.2 million seed round in June 2023 led by ARTIS Ventures, with ARTIS partner Ameena El-Bibany joining the board. In January 2025 it was selected as one of 18 startups in the SLAS 2025 Innovation AveNEW program for high-throughput laboratory sciences. Company leadership described the seed financing as a significant milestone and said other milestones had been reached but were not yet disclosed. Headcount is reported as small, in the 1-10 to 1-50 range depending on the source.

Latest developments

In September 2025 the company posted a news item titled "Creating new standards for diagnostics research." Earlier in 2025 it was named an SLAS Innovation AveNEW company. A startup-data listing records Vento and Hawktail among its investors, with the most recent recorded activity in May 2024.